1. Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 2.0 μg/mL can bind Recombinant Human IL-6 Protein (rp156005) with the EC50 of 43.35 ng/mL. 2. Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 1.0 μg/mL can bind Vobarilizumab (anti-IL-6Ra) (Ab175700) with the EC50 of 67.99 ng/mL. 3. Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 1.0 μg/mL can bind Tocilizumab (anti-IL-6R) (T412004) with the EC50 of 21.05 ng/mL.
Purity: ≥95%, by SDS-PAGE visualized with Coomassie® Blue Staining. Protein Function: The multifunctional factor interleukin 6 (IL-6) exerts its activities through binding to a high-affinity receptor complex consisting of two membrane glycoproteins: an 80 kDa component receptor that binds IL-6 with low affinity (IL-6R alpha ) and a signal-transducing component of 130 kDa (gp130) that does not bind IL-6 by itself, but is required for high-affinity binding of IL-6 by the complex. Both components of the receptor complex, IL-6R alpha and gp130 have been cloned, sequenced, and expressed. A soluble form of the IL-6R alpha has been found in the urine of healthy adult humans. This soluble receptor apparently arises from proteolytic cleavage of membrane-bound IL-6R alpha. No naturally-occurring mRNA encoding a truncated form of the IL-6R alpha has been reported. Soluble forms of human and murine IL-6R alpha s have been constructed, however, by insertion of termination codons into the regions of the IL-6R alpha cDNAs encoding the external portions of the receptors and prior to the transmembrane domains. These soluble receptors have been expressed in COS-7 and CHO cells and have been shown to bind to IL-6 in solution and to augment the activity of IL-6 as a result of the binding of the IL-6/IL-6R alpha complex to membrane-bound gp130.
1. Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 2.0 μg/mL can bind Recombinant Human IL-6 Protein (rp156005) with the EC50 of 43.35 ng/mL. 2. Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 1.0 μg/mL can bind Vobarilizumab (anti-IL-6Ra) (Ab175700) with the EC50 of 67.99 ng/mL. 3. Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 1.0 μg/mL can bind Tocilizumab (anti-IL-6R) (T412004) with the EC50 of 21.05 ng/mL.
60.0-80.8 kDa, under reducing conditions; 60.0-80.7kDa, under non-reducing conditions
分子类型
蛋白质
产品线
生物产品
储存与运输
物理形态
冻干(Lyophilized)
储存缓冲液
Lyophilized from PBS, pH 7.4
复溶
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute at 1.0 mg/mL in sterile distilled water. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
储存条件
-20°C储存,避免反复冻融
运输条件
超低温运输
稳定性与储存
在 -20°C 下可保存 1 年。避免冷冻/解冻循环。
图片
Recombinant Human IL-6R alpha Protein (rp181252) - Binding Activity Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 2.0 μg/mL can bind Recombinant Human IL-6 Protein (rp156005) with the EC₅₀ of 43.35 ng/mL.
Recombinant Human IL-6R alpha Protein (rp181252) - ELISA Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 1.0 μg/mL can bind Vobarilizumab (anti-IL-6Ra) (Ab175700) with the EC₅₀ of 67.99 ng/mL.
Recombinant Human IL-6R alpha Protein (rp181252) - ELISA Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 1.0 μg/mL can bind Tocilizumab (anti-IL-6R) (T412004) with the EC₅₀ of 21.05 ng/mL.
Recombinant Human IL-6R alpha Protein (rp181252) - SDS-PAGE 2 μg/lane of Recombinant Human IL-6R alpha Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 60.0-80.8 kDa under reducing conditions and 60.0-80.7 kDa under non-reducing conditions.
ZJ24F0708062
危险品化学品经营许可证（带存储）